Anti-cancer agents for breast cancer treatment during pregnancy.

摘要

We read with great interest the recent article by Guidroz et al. [1] on the management of pregnant women with breast cancer. We agree with the authors that chemotherapy should be postponed until the second trimester of pregnancy, and that some regimens can be introduced during pregnancy with limited short-term toxicity for both the mother and the fetus [2].However, the authors assume that taxanes should be avoided during pregnancy given the absence of data regarding their safety, whereas recent clinical data (n = 42) seem to be quite reassuring [3]. Moreover, recommendations from a recent international experts meeting stated that taxanes may be safely used during the second and third trimesters of pregnancy [4]. Finally, recent data indicate that pregnancy-associated breast cancers are as chemosensitive as other breast cancers, highlighting the potential role of taxanes in this setting [5].